Controlled Clinical Trial
doi: 10.1016/j.clinimag.2013.02.001.
Epub 2013 Mar 20.
Clinical MRI for iron detection in Parkinson's disease
Affiliations
- PMID: 23522789
- DOI: 10.1016/j.clinimag.2013.02.001
Item in Clipboard
Controlled Clinical Trial
Clinical MRI for iron detection in Parkinson's disease
Clin Imaging.
2013 Jul-Aug.
Abstract
We studied nonheme iron in Parkinson's disease (PD) using clinically available MRI in 36 patients and 21 healthy volunteers. The subjects underwent thorough clinical investigation, including 3-T MRI. Quantitative R2* was able to reflect symptoms of PD. In addition, the clinically used susceptibility-weighted imaging differentiated between controls and patients, whereas T2-weighted imaging did not. Disease-related changes were present not only in substantia nigra but also in globus pallidus. Such changes are associated with neurodegeneration, reflecting the severity of motor impairment.
Copyright © 2013 Elsevier Inc. All rights reserved.
Similar articles
-
T2 relaxation time in patients with Parkinson's disease.Neurology. 1993 Apr;43(4):697-700. doi: 10.1212/wnl.43.4.697. Neurology. 1993. PMID: 8469325
-
Quantitative Susceptibility Mapping in Parkinson's Disease.PLoS One. 2016 Sep 6;11(9):e0162460. doi: 10.1371/journal.pone.0162460. eCollection 2016. PLoS One. 2016. PMID: 27598250 Free PMC article.
-
Serum cholesterol and nigrostriatal R2* values in Parkinson's disease.PLoS One. 2012;7(4):e35397. doi: 10.1371/journal.pone.0035397. Epub 2012 Apr 17. PLoS One. 2012. PMID: 22530017 Free PMC article.
-
[The role of magnetic resonance imaging in the diagnosis of Hallervorden-Spatz disease].Rinsho Shinkeigaku. 1990 Sep;30(9):972-7. Rinsho Shinkeigaku. 1990. PMID: 2265508 Review. Japanese.
-
Does structural neuroimaging reveal a disturbance of iron metabolism in Parkinson's disease? Implications from MRI and TCS studies.J Neural Transm (Vienna). 2012 Dec;119(12):1523-8. doi: 10.1007/s00702-012-0873-0. Epub 2012 Aug 9. J Neural Transm (Vienna). 2012. PMID: 22875636 Review.
Cited by
-
Oxytosis/Ferroptosis in Neurodegeneration: the Underlying Role of Master Regulator Glutathione Peroxidase 4 (GPX4).Mol Neurobiol. 2024 Mar;61(3):1507-1526. doi: 10.1007/s12035-023-03646-8. Epub 2023 Sep 19. Mol Neurobiol. 2024. PMID: 37725216 Review.
-
Curcumin and N-Acetylcysteine Nanocarriers Alone or Combined with Deferoxamine Target the Mitochondria and Protect against Neurotoxicity and Oxidative Stress in a Co-Culture Model of Parkinson's Disease.Antioxidants (Basel). 2023 Jan 5;12(1):130. doi: 10.3390/antiox12010130. Antioxidants (Basel). 2023. PMID: 36670992 Free PMC article.
-
Discovery and validation of Ferroptosis-related molecular patterns and immune characteristics in Alzheimer's disease.Front Aging Neurosci. 2022 Nov 23;14:1056312. doi: 10.3389/fnagi.2022.1056312. eCollection 2022. Front Aging Neurosci. 2022. PMID: 36506471 Free PMC article.
-
An Updated Overview of the Magnetic Resonance Imaging of Brain Iron in Movement Disorders.Behav Neurol. 2022 Feb 24;2022:3972173. doi: 10.1155/2022/3972173. eCollection 2022. Behav Neurol. 2022. PMID: 35251368 Free PMC article. Review.
-
Low plasma serotonin linked to higher nigral iron in Parkinson's disease.Sci Rep. 2021 Dec 21;11(1):24384. doi: 10.1038/s41598-021-03700-2. Sci Rep. 2021. PMID: 34934078 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
